Is NSC 93752 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use NSC 93752? Is NSC 93752 safe for nursing mother and child? Does NSC 93752 extracts into breast milk? Does NSC 93752 has any long term or short term side effects on infants? Can NSC 93752 influence milk supply or can NSC 93752 decrease milk supply in lactating mothers?

• DrLact safety Score for NSC 93752 is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of NSC 93752 may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that NSC 93752 may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using NSC 93752 .
• It is recommended to evaluate the advantage of not breastfeeding while using NSC 93752 Vs not using NSC 93752 And continue breastfeeding.
• While using NSC 93752 Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Ergot derivative which is used in the prevention and treatment of postpartum hemorrhage. It has frequent and serious side effects (nausea, vomiting, headache, hypertension, arrhythmias, angina and infarction) that do not occur with oxytocin, so the latter is preferable to reduce the risk of postpartum hemorrhage.They have occurred serious poisonings in infants when giving it intramuscularly due to confusion with other medication for newborn (Dargaville 1998). Data on excretion into breast milk is lacking; the excretion of another product of the same family and similar chemical structure, Methylergometrine, has been shown to be negligible. It may cause shortening of the duration of breastfeeding (Jordan 2009, Begley 1990) by decreasing the concentration of prolactin and inhibiting lactation (Canales 1976, Shane 1974). These effects have been demonstrated to be much more intense that in the case of Methylergometrine.